PFE’s PF-00299804 pan-HER inhibitor (a/k/a PF-299) shows promising phase-2 interim results in first-line NSCLC, although there are not yet any survival data of consequence:
PFE is also testing PF-00299804 in a phase-3 trial vs placebo in NSCLC patients who failed prior therapy with Tarceva or Iressa; results are expected in Nov 2012 (http://clinicaltrials.gov/ct2/show/NCT01000025 ).
Market Data 
Markets 
AI
